Axa S.A. Reduces Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Axa S.A. reduced its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 19.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 278,266 shares of the company’s stock after selling 66,387 shares during the period. Axa S.A.’s holdings in NewAmsterdam Pharma were worth $7,151,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. National Bank of Canada FI purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in NewAmsterdam Pharma during the 4th quarter worth approximately $80,000. Barclays PLC lifted its stake in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $154,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $221,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $19.00 on Wednesday. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -7.31 and a beta of 0.01. The business’s 50 day moving average price is $19.65 and its 200-day moving average price is $21.24. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NAMS has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Buy” and a consensus target price of $43.33.

Insiders Place Their Bets

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at approximately $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director James N. Topper purchased 4,005 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the transaction, the director now directly owns 3,012,434 shares of the company’s stock, valued at $63,321,362.68. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.